Efficacy News and Research

RSS

TRI awarded RSC contract to support domestic, international clinical research programs

Technical Resources International, Inc. is pleased to announce that TRI has been awarded the Regulatory Support Center contract by the U.S. National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health, Department of Health and Human Services.

17 Aug 2010

Intercell reports significant increase in second quarter revenue

Today, Intercell AG announced its financial results for Q2 and H1 2010.IXIARO/JESPECT sales increased significantly from EUR 2.4m in Q2 2009 to EUR 5.2m in Q2 2010 Continued focus on growing marketing and sales of product in traveler and military markets

17 Aug 2010

Shah discusses foreign aid efficiency

At an event on Friday in Seattle, USAID Administrator Rajiv Shah discussed foreign aid efficacy and ways "to streamline the federal agency and to help make the whole U.S. aid budget easier to understand and track," the Associated Press/Seattle Times reports. Shah said that the Obama administration is concerned about foreign aid transparency and its effectiveness, adding: "The president continues to live up to the overall commitment to develop foreign assistance."

16 Aug 2010

NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies

NanoViricides, Inc., reports that its anti-Herpes drug candidates demonstrated significant efficacy in the recently completed cell culture studies. The studies were performed in the laboratory of Dr. Ken Rosenthal at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

16 Aug 2010

Pathology experts meet to at SESPM to update new advances in breast surgery

Over 1.500 breast pathology experts will meet between the 20th and 22nd of October in the 16th World Congress of the Senologic International Society (SIS). This meeting and the 29th Congress of the Spanish Society of Senology and Breast Diseases (SESPM) will take place in the Valencia, coinciding with the International Breast Cancer Day.

16 Aug 2010

Watson to launch ella emergency contraceptive in fourth-quarter 2010

Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.

16 Aug 2010

BIOTRONIK DREAMS implanted in first patient as part of BIOSOLVE-I clinical study

A significant milestone has been reached in the development of a new therapy for patients suffering from coronary artery disease. On July 27, 2010 the BIOTRONIK DREAMS (Drug Eluting Absorbable Metal Scaffold) was successfully implanted in the first patient by Prof. Dr. Michael Haude at the Lukaskrankenhaus in Neuss, Germany as part of the first-in-man clinical study BIOSOLVE-I.

13 Aug 2010

Catalyst second-quarter net loss decreases to $1,328,541

Catalyst Pharmaceutical Partners, Inc. today announced its financial results for the second quarter and six months ended June 30, 2010.

13 Aug 2010

ISW calls upon states to consider community-based programs as treatment for sex offenders

A recent analysis conducted by the Associated Press revealed that the 20 states with civil commitment laws will spend nearly $500 million in 2010 to incarcerate only 5,000 offenders. According to experts at the Boston-based Institute for Sexual Wellness (ISW), states concerned with how to pay for these programs over the long term should investigate community-based programs. Not only are such programs available at a fraction of the cost of civil commitment, but they are demonstrating high success in preventing recidivism.

13 Aug 2010

Derma Sciences second-quarter net sales increase 14% to $13.2 million

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and six months ended June 30, 2010.

13 Aug 2010

Combination of fungi, insecticides can combat malaria mosquitoes: Research

A combination of fungal spores and chemical insecticides are an effective way of combating insecticide-resistant malaria mosquitoes. Researchers at Wageningen UR and from Benin, West Africa, have shown that fungi and insecticides reinforce each other´s efficacy, and that the effect of using a combination of both is greater than the sum of using the two methods separately. Their article in the August edition of PLoS One (Public Library of Science) claims that biological and chemical methods of fighting malaria can and should be used together.

13 Aug 2010

Humanetics Corporation secures license to provide treatment for ionizing radiation exposure

In a move likely to secure its place as a leading provider of medical radiation countermeasures, Humanetics Corporation today announced that it has secured exclusive worldwide licenses to two new treatments that provide short and long-term post-exposure protection from ionizing radiation acquired during a terrorist act, nuclear or radiological attack or accident, as part of cancer radiotherapy or even during routine diagnostic CT scans.

13 Aug 2010

Gore announces first implantation in IDE clinical study of ACUSEAL Vascular Graft in hemodialysis patients

W. L. Gore & Associates reported that the first patient, in an Investigational Device Exemption (IDE) clinical study evaluating the self sealing GORE® ACUSEAL Vascular Graft in patients on hemodialysis, has been surgically implanted with the device. The successful surgical procedure was performed on July 29, 2010 at Greenville Hospital System in Greenville, South Carolina. Less than 24 hours after the device was implanted it was successfully cannulated or punctured for initial hemodialysis access.

13 Aug 2010

Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer

Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.0 million financing with two existing institutional shareholders, both of which are affiliates of Xmark Opportunity Partners, LLC.

13 Aug 2010

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

13 Aug 2010

Transgenomic second-quarter net loss increases to $1.1 million

Transgenomic, Inc. today reported financial results for the three and six months ended June 30, 2010, and provided a business update.

13 Aug 2010

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.

12 Aug 2010

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Amorfix Life Sciences, a product development company focused on misfolded protein diseases, today announced its operational and financial results for the three months ended June 30, 2010.

12 Aug 2010

Pharmasset receives fast track designation from FDA for PSI-7977

Pharmasset, Inc. has received fast track designation from the U.S. Food and Drug Administration for PSI-7977 for the treatment of chronic hepatitis C virus infection. PSI-7977 is an oral uridine nucleotide analog polymerase inhibitor of HCV. Pharmasset recently completed dosing in a 28 day Phase 2a trial to evaluate PSI-7977 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in treatment-naive patients chronically infected with HCV genotype 1.

12 Aug 2010

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Evotec AG today reported financial results and corporate updates for the first half of 2010.

12 Aug 2010

Efficacy News and Research

TRI awarded RSC contract to support domestic, international clinical research programs

Intercell reports significant increase in second quarter revenue

Shah discusses foreign aid efficiency

NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies

Pathology experts meet to at SESPM to update new advances in breast surgery

Watson to launch ella emergency contraceptive in fourth-quarter 2010

BIOTRONIK DREAMS implanted in first patient as part of BIOSOLVE-I clinical study

Catalyst second-quarter net loss decreases to $1,328,541

ISW calls upon states to consider community-based programs as treatment for sex offenders

Derma Sciences second-quarter net sales increase 14% to $13.2 million

Combination of fungi, insecticides can combat malaria mosquitoes: Research

Humanetics Corporation secures license to provide treatment for ionizing radiation exposure

Gore announces first implantation in IDE clinical study of ACUSEAL Vascular Graft in hemodialysis patients

Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

Transgenomic second-quarter net loss increases to $1.1 million

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Pharmasset receives fast track designation from FDA for PSI-7977

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News